pentobarbital will decrease the level or outcome of lumacaftor/ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.
pentobarbital will lessen the extent or result of repaglinide by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of.
Following oral or parenteral administration, barbiturates readily cross the placental barrier and therefore are distributed in the course of fetal tissues with optimum concentrations present in the placenta, fetal liver, and brain; fetal blood degrees tactic maternal blood ranges subsequent parenteral administration
pentobarbital will decrease the level or outcome of apremilast by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Stay away from or Use Alternate Drug. Coadministration with strong CYP inducers results in a substantial reduce of systemic publicity of apremilast, which may result in loss of efficacy
Watch Closely (1)pentobarbital will lower the extent or result of hydrocodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Carefully. Warning when discontinuing CYP3A4 inducers which are coadministered with hydrocodone; plasma concentrations of hydrocodone may possibly increase and can result in possibly fatal respiratory depressionSerious - Use Choice (one)hydrocodone, pentobarbital.
pentobarbital decreases levels of vandetanib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Avoid coadministration with potent CYP3A4 inducers; these drugs cut down exposure to vandetanib by approximately forty%.
pentobarbital will decrease the level or effect of saxagliptin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
pentobarbital will lower the extent or result of dexamethasone by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check.
pentobarbital will decrease the level or result of isradipine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Importance Mysterious.
pentobarbital will decrease the level or outcome of conjugated estrogens, vaginal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.
pentobarbital will decrease the extent or impact of disopyramide by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Small/Importance Mysterious.
Contraindicated (1)pentobarbital decreases amounts of panobinostat by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Potent CYP3A4 inducers can lessen panobinostat concentrations by ~70% and cause therapy failure.
pentobarbital will minimize the level or outcome of fesoterodine by read more impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe.
pentobarbital will minimize the extent or effect of galantamine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Small/Significance Mysterious.